Skip to content
Sign in

Company

Lynk Pharmaceuticals

Open structure map

Structure of Lynk Pharmaceuticals

Lynk Pharmaceuticals

Company

8 connections
UpstreamSupply and dependency5 of 6
DownstreamCustomers
PeersCompetition and partners
Relationship began2026
Lynk PharmaceuticalsCompany · 8 connections
Layer 1

UpstreamSupply and dependency5

DownstreamCustomers1

PeersCompetition and partners2

Place in the network

No. 2013 of 118934top 2%down 287 places this week

8 direct links

In a group of 287 closely linked entities, around

Weighted by public relations with evidence, recomputed daily.

Relations

Arrows show the direction of the relationship. Filter to focus on a business area.

  • Fact96%
    View evidence
    • MediaGDELT Global Knowledge Graph2026-10-28 15:30
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 13:00
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 12:00
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 11:45
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 11:30
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 11:00
      View source
    • CompanyPR Newswire news releases2026-10-28
      The company was founded by senior R&D leaders from Pfizer, MSD, and Johnson & Johnson, focusing on the JAK-STAT and expanding to TYK2 signaling pathways, and mastering targeted protein degradation.
      View source
  • Fact96%
    View evidence
    • MediaGDELT Global Knowledge Graph2026-10-28 15:30
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 13:00
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 12:00
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 11:45
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 11:30
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 11:00
      View source
    • CompanyPR Newswire news releases2026-10-28
      The company was founded by senior R&D leaders from Pfizer, MSD, and Johnson & Johnson, focusing on the JAK-STAT and expanding to TYK2 signaling pathways, and mastering targeted protein degradation.
      View source
  • Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-11-02 17:00
      The company combines AI-assisted drug design, comprehensive biological evaluation, and protein degradation technologies into an integrated innovative R&D platform
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 15:30
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 13:00
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 12:00
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 11:45
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 11:30
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 11:00
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 09:30
      View source
    • CompanyPR Newswire news releases2026-10-28
      The company combines AI-assisted drug design, comprehensive biological evaluation, and protein degradation technologies into an integrated innovative R&D platform spanning target discovery, molecular design, translational research, and clinical development to advance differentia…
      View source
  • Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-11-02 17:00
      The company combines AI-assisted drug design, comprehensive biological evaluation, and protein degradation technologies into an integrated innovative R&D platform
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 15:30
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 13:00
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 12:00
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 11:45
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 11:30
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 11:00
      View source
    • CompanyPR Newswire news releases2026-10-28
      The company combines AI-assisted drug design, comprehensive biological evaluation, and protein degradation technologies into an integrated innovative R&D platform spanning target discovery, molecular design, translational research, and clinical development to advance differentia…
      View source
  • Lynk Pharmaceuticalspartners with →Simcere
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-11-06 12:30
      Lynk Pharmaceuticals has entered into a commercialization collaboration with Simcere to jointly advance the development and commercialization of zemprocitinib across rheumatology (rheumatoid arthritis, ankylosing spondylitis) and dermatology indications.
      View source
  • Fact90%
    View evidence
    • MediaGDELT Global Knowledge Graph2026-10-28 15:30
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 12:00
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 11:45
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 11:30
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 11:00
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 09:30
      View source
    • CompanyPR Newswire news releases2026-10-28
      Lynk Pharmaceuticals is a clinical-stage innovative drug company focused on autoimmune and inflammatory diseases, committed to addressing unmet clinical needs through first-in-class innovation, developing differentiated small-molecule therapies, and providing superior oral alter…
      View source
  • Lynk Pharmaceuticalspartners with →Simcere Pharmaceutical Group
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-11-02 17:00
      In March 2022, Lynk Pharmaceuticals and Simcere entered into a commercialization collaboration
      View source
    • CompanyPR Newswire news releases2026-11-02 17:00
      Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), today announced that it has expanded its commercialization collaboration with Simcere Pharmaceutical Group Limited ("Simcere") for zemprocitinib
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 15:30
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 13:00
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 12:00
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 11:45
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 11:30
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 11:00
      View source
    • MediaGDELT Global Knowledge Graph2026-10-28 09:30
      View source
    • CompanyPR Newswire news releases2026-10-28
      In March 2022, Lynk Pharmaceuticals entered into a commercialization collaboration with Simcere to jointly advance the commercialization of zemprocitinib for rheumatoid arthritis and ankylosing spondylitis in Greater China.
      View source
  • Lynk Pharmaceuticalsuses →Protein degradation
    Fact55%
    View evidence
    • MediaGDELT Global Knowledge Graph2026-10-28 09:30
      View source

Showing 1 to 8 of 9

Claims

Read the assertion alongside its sources. Expand a row to inspect the evidence.

FactEvidence 1
partners withSimcere

Lynk Pharmaceuticals has entered into a commercialization collaboration with Simcere to jointly advance the development and commercialization of zemprocitinib across rheumatology (rheumatoid arthritis, ankylosing spondylitis) and dermatology indications.

PR Newswire news releases · 2026-11-06 12:30

View evidence
  • CompanyPR Newswire news releases2026-11-06 12:30
    Lynk Pharmaceuticals has entered into a commercialization collaboration with Simcere to jointly advance the development and commercialization of zemprocitinib across rheumatology (rheumatoid arthritis, ankylosing spondylitis) and dermatology indications.
    View source
FactEvidence 8

The company combines AI-assisted drug design, comprehensive biological evaluation, and protein degradation technologies into an integrated innovative R&D platform

PR Newswire news releases · GDELT Global Knowledge Graph · 2026-11-02 17:00

View evidence
  • CompanyPR Newswire news releases2026-11-02 17:00
    The company combines AI-assisted drug design, comprehensive biological evaluation, and protein degradation technologies into an integrated innovative R&D platform
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 15:30
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 13:00
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 12:00
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 11:45
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 11:30
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 11:00
    View source
  • CompanyPR Newswire news releases2026-10-28
    The company combines AI-assisted drug design, comprehensive biological evaluation, and protein degradation technologies into an integrated innovative R&D platform spanning target discovery, molecular design, translational research, and clinical development to advance differentia…
    View source
FactEvidence 9

The company combines AI-assisted drug design, comprehensive biological evaluation, and protein degradation technologies into an integrated innovative R&D platform

PR Newswire news releases · GDELT Global Knowledge Graph · 2026-11-02 17:00

View evidence
  • CompanyPR Newswire news releases2026-11-02 17:00
    The company combines AI-assisted drug design, comprehensive biological evaluation, and protein degradation technologies into an integrated innovative R&D platform
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 15:30
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 13:00
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 12:00
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 11:45
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 11:30
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 11:00
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 09:30
    View source
  • CompanyPR Newswire news releases2026-10-28
    The company combines AI-assisted drug design, comprehensive biological evaluation, and protein degradation technologies into an integrated innovative R&D platform spanning target discovery, molecular design, translational research, and clinical development to advance differentia…
    View source
FactEvidence 10

In March 2022, Lynk Pharmaceuticals and Simcere entered into a commercialization collaboration

PR Newswire news releases · GDELT Global Knowledge Graph · 2026-11-02 17:00

View evidence
  • CompanyPR Newswire news releases2026-11-02 17:00
    In March 2022, Lynk Pharmaceuticals and Simcere entered into a commercialization collaboration
    View source
  • CompanyPR Newswire news releases2026-11-02 17:00
    Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), today announced that it has expanded its commercialization collaboration with Simcere Pharmaceutical Group Limited ("Simcere") for zemprocitinib
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 15:30
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 13:00
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 12:00
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 11:45
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 11:30
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 11:00
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 09:30
    View source
  • CompanyPR Newswire news releases2026-10-28
    In March 2022, Lynk Pharmaceuticals entered into a commercialization collaboration with Simcere to jointly advance the commercialization of zemprocitinib for rheumatoid arthritis and ankylosing spondylitis in Greater China.
    View source
FactEvidence 7

The company was founded by senior R&D leaders from Pfizer, MSD, and Johnson & Johnson, focusing on the JAK-STAT and expanding to TYK2 signaling pathways, and mastering targeted protein degradation.

GDELT Global Knowledge Graph · PR Newswire news releases · 2026-10-28 15:30

View evidence
  • MediaGDELT Global Knowledge Graph2026-10-28 15:30
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 13:00
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 12:00
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 11:45
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 11:30
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 11:00
    View source
  • CompanyPR Newswire news releases2026-10-28
    The company was founded by senior R&D leaders from Pfizer, MSD, and Johnson & Johnson, focusing on the JAK-STAT and expanding to TYK2 signaling pathways, and mastering targeted protein degradation.
    View source
FactEvidence 7

The company was founded by senior R&D leaders from Pfizer, MSD, and Johnson & Johnson, focusing on the JAK-STAT and expanding to TYK2 signaling pathways, and mastering targeted protein degradation.

GDELT Global Knowledge Graph · PR Newswire news releases · 2026-10-28 15:30

View evidence
  • MediaGDELT Global Knowledge Graph2026-10-28 15:30
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 13:00
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 12:00
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 11:45
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 11:30
    View source
  • MediaGDELT Global Knowledge Graph2026-10-28 11:00
    View source
  • CompanyPR Newswire news releases2026-10-28
    The company was founded by senior R&D leaders from Pfizer, MSD, and Johnson & Johnson, focusing on the JAK-STAT and expanding to TYK2 signaling pathways, and mastering targeted protein degradation.
    View source

Showing 1 to 6 of 9

Market and valuation

Valuation data is available on Pro and Research.

Included in Pro

Suggest a page to watch

Know a page of this company that matters, such as pricing, a changelog, terms or careers? Suggest it. We read every suggestion; a page we add is watched for everyone, and we only count a change when two looks in a row agree.

Sign in to suggest a page

Not available: Company signals · Financials · Filings · Sites · Guidance